These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 17890862

  • 1. Long-term safety and efficacy of ivabradine in patients with chronic stable angina.
    López-Bescós L, Filipova S, Martos R.
    Cardiology; 2007; 108(4):387-96. PubMed ID: 17890862
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus.
    Borer JS, Tardif JC.
    Am J Cardiol; 2010 Jan 01; 105(1):29-35. PubMed ID: 20102886
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of I(f) inhibition with ivabradine in different subpopulations with stable angina pectoris.
    Tendera M, Borer JS, Tardif JC.
    Cardiology; 2009 Jan 01; 114(2):116-25. PubMed ID: 19468225
    [Abstract] [Full Text] [Related]

  • 4. Dipyridamole in chronic stable angina pectoris; a randomized, double blind, placebo-controlled, parallel group study.
    Picano E, PISA (Persantin In Stable Angina) study group.
    Eur Heart J; 2001 Oct 01; 22(19):1785-93. PubMed ID: 11549300
    [Abstract] [Full Text] [Related]

  • 5. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
    Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L, ERICA Investigators.
    J Am Coll Cardiol; 2006 Aug 01; 48(3):566-75. PubMed ID: 16875985
    [Abstract] [Full Text] [Related]

  • 6. Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study.
    Köster R, Kaehler J, Meinertz T, REDUCTION Study Group.
    Am Heart J; 2009 Oct 01; 158(4):e51-7. PubMed ID: 19781403
    [Abstract] [Full Text] [Related]

  • 7. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K, Ferrari R, Tendera M, Steg PG, Ford I, BEAUTIFUL Steering Committee.
    Am Heart J; 2006 Nov 01; 152(5):860-6. PubMed ID: 17070146
    [Abstract] [Full Text] [Related]

  • 8. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N.
    Therapie; 2009 Nov 01; 64(2):111-4. PubMed ID: 19664404
    [Abstract] [Full Text] [Related]

  • 9. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.
    Ruzyllo W, Tendera M, Ford I, Fox KM.
    Drugs; 2007 Nov 01; 67(3):393-405. PubMed ID: 17335297
    [Abstract] [Full Text] [Related]

  • 10. Ivabradine: beyond heart rate control.
    Riccioni G, Vitulano N, D'Orazio N.
    Adv Ther; 2009 Jan 01; 26(1):12-24. PubMed ID: 19165437
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
    Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL Investigators.
    Eur Heart J; 2009 Oct 01; 30(19):2337-45. PubMed ID: 19720635
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Review of the If selective channel inhibitor ivabradine in the treatment of chronic stable angina.
    Prasad UK, Gray D, Purcell H.
    Adv Ther; 2009 Feb 01; 26(2):127-37. PubMed ID: 19259630
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Focus on ivabradine: a new heart rate-controlling drug.
    Riccioni G.
    Expert Rev Cardiovasc Ther; 2009 Feb 01; 7(2):107-13. PubMed ID: 19210206
    [Abstract] [Full Text] [Related]

  • 17. Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study.
    Müller-Werdan U, Stöckl G, Ebelt H, Nuding S, Höpfner F, Werdan K, ADDITIONS Study Investigators.
    Exp Gerontol; 2014 Nov 01; 59():34-41. PubMed ID: 25193811
    [Abstract] [Full Text] [Related]

  • 18. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine.
    Doesch AO, Celik S, Ehlermann P, Frankenstein L, Zehelein J, Koch A, Katus HA, Dengler TJ.
    Transplantation; 2007 Oct 27; 84(8):988-96. PubMed ID: 17989604
    [Abstract] [Full Text] [Related]

  • 19. Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.
    Sulfi S, Timmis AD.
    Int J Clin Pract; 2006 Feb 27; 60(2):222-8. PubMed ID: 16451297
    [Abstract] [Full Text] [Related]

  • 20. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
    Koren MJ, Crager MR, Sweeney M.
    J Am Coll Cardiol; 2007 Mar 13; 49(10):1027-34. PubMed ID: 17349881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.